`571.272.7822
`
`
`
`
`
`
`
`
` Paper No. 46
`
` Entered: November 28, 2017
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`OSI PHARMACEUTICALS, LLC
`and GENENTECH, INC.,
`
`Petitioner,
`v.
`ARCH DEVELOPMENT CORP. and
`DANA-FARBER CANCER INSTITUTE, INC.,
`
`Patent Owner.
`____________
`
`Case IPR2016-01034
`Patent 7,838,512 B1
`____________
`
`
`Before LORA M. GREEN, TINA E. HULSE, and
`ROBERT A. POLLOCK, Administrative Patent Judges.
`
`POLLOCK, Administrative Patent Judge.
`
`
`
`
`DECISION
`Denying Request for Rehearing
`37 C.F.R. §42.71
`
`
`
`
`
`
`IPR2016-01034
`Patent 7,838,512 B1
`
` INTRODUCTION
`
`A.
`
`Background
`In our Final Written Decision (Paper 43, “Dec.”), we held that claims
`1–3, 5, and 6 (collectively, “the challenged claims”) of U.S. Patent
`No. 7,838,512 B1 (Ex. 1001, “the ’512 patent”) were unpatentable over
`Akinaga,1 in view of the knowledge of a person of ordinary skill in the art,
`Seynaeve,2 Friedman,3 and Tam4 (Ground IV). See Dec. 38–39.5 Patent
`Owner timely filed a Request for Rehearing requesting that we vacate the
`portion of our Decision relating to that Ground. Paper 44 (“Reh’g Req.”).6
`We did not authorize any response to the Request for Rehearing.
`For the reasons that follow, we deny Patent Owner’s Request for
`Rehearing.
`
`
`1 Shiro Akinaga et al., Enhancement of Antitumor Activity of Mitomycin C In
`Vitro and In Vivo by UCN-01, a Selective Inhibitor of Protein Kinase C, 32
`CANCER CHEMOTHERAPY AND PHARMACOLOGY 183–89 (1993). Ex. 1004.
`2 Caroline M. Seynaeve et al., Cell Cycle Arrest and Growth Inhibition by
`the Protein Kinase Antagonist UCN-01 in Human Breast Carcinoma Cells,
`53 CANCER RES. 2081–86 (1993). Ex. 1014.
`3 BethAnn Friedman et al., Regulation of the Epidermal Growth Factor
`Receptor by Growth-Modulating Agents: Effects of Staurosporine, a Protein
`Kinase Inhibitor, 50 CANCER RES. 533–38 (1990). Ex. 1031.
`4 Sun W. Tam and Robert Schlegel, Staurosporine Overrides Checkpoints
`for Mitotic Onset in BHK Cells, 3 CELL GROWTH & DIFFERENTIATION 811–
`17 (1992). Ex. 1012.
`5 We note that Paper 43, the Final Written Decision, issued September 11,
`2017, contains font changes introduced during the uploading process. Paper
`43 is hereby republished to eliminate the unintended font changes.
`6 We further found claim 6 invalid for reasons not at issue here.
`2
`
`
`
`IPR2016-01034
`Patent 7,838,512 B1
`Standard for Reconsideration
`B.
`The applicable standard for a request for rehearing is set forth in
`37 C.F.R. § 42.71(d), which provides in relevant part:
`A party dissatisfied with a decision may file a request for
`rehearing, without prior authorization from the Board. The
`burden of showing a decision should be modified lies with the
`party challenging the decision. The request must specifically
`identify all matters the party believes the Board misapprehended
`or overlooked, and the place where each matter was previously
`addressed in a motion, an opposition, or a reply.
` ANALYSIS
`
`Patent Owner argues that we should grant its Request for Rehearing
`because our conclusion is based on findings that 1) staurosporine was
`known to inhibit the tyrosine kinase c-src in human and animal cells; and 2)
`that staurosporine has a structure and mechanism of action similar to UCN-
`01, such that one of ordinary skill in the art would expect UCN-01 to
`likewise inhibit tyrosine kinases such as c-src. See Reh’g Req. 1–2. As an
`initial matter, we reject the premise of Patent Owner’s argument that our
`Decision stands or falls on whether one of ordinary skill in the art would
`have understood that UCN-01 inhibits the tyrosine kinase c-src in human
`and animal cells.
`As illustrated in claim 1, the challenged claims are generally directed
`to administering a chemotherapeutic DNA damaging agent in combination
`with a low molecular weight tyrosine kinase inhibitor.7 According to the
`Specification, this combination is beneficial because treatment with a DNA
`damaging agent promotes cell cycle arrest, during which time cells attempt
`
`7 Patent Owner concedes that claim 1 is representative and does not argue
`claims 2, 3, 5, and 6 separately. See, e.g., PO Resp. 3.
`3
`
`
`
`IPR2016-01034
`Patent 7,838,512 B1
`to repair DNA damage before undergoing mitosis and subsequent cell
`division. See Dec. 4–6. Tyrosine kinase inhibitors, however, force cells to
`override the cell cycle arrest checkpoint and enter mitosis before repairs are
`complete, thereby enhancing the cytotoxic effects of the DNA damaging
`agents. Id.
`As discussed in our Decision, Akinaga examines the effect of
`UCN-01 alone, and in combination with the DNA damaging agent
`mitomycin C. See Dec. 27–28; Ex. 1004. Noting that the two compounds
`had 1) complementary effects in delaying cell cycle progression; and 2)
`synergistic cytotoxic and antitumor effects, Akinaga expressly suggests the
`combination of UCN-01 and DNA-damaging agents for cancer
`chemotherapy. Id. Seynaeve establishes that UCN-01 inhibits multiple
`tyrosine kinases in human breast cancer cells coincident with promoting
`cell cycle arrest. Dec. 28–29, 34–35; Ex. 1014. Accordingly, “Seynaeve
`proposes a link between UCN-01’s inhibitory effects on tyrosine kinases
`and its inhibitory effects on the cell cycle.” Dec. 29.8
`Akinaga further suggests combining a chemotherapeutic DNA
`damaging agent with UCN-01 because the two compounds cause delays in
`different stages of the cell cycle and result in synergistic cytotoxic and
`antitumor effects, whereas Seynaeve examines the effects of UCN-01 on
`the cell cycle of human carcinoma cells and shows that UCN-01 is a
`tyrosine kinase inhibitor. See Dec. 37–38. Because both references
`
`
`8 Considering Seynaeve teachings with respect to UCN-01, we reject Patent
`Owner’s contention that “there is no evidence from which one can
`reasonably find that Petitioner carried its burden of proving that people of
`ordinary skill in the art considered either staurosporine or UCN-01 to be
`tyrosine kinase inhibitors.” See Reh’g. Req. 6.
`4
`
`
`
`IPR2016-01034
`Patent 7,838,512 B1
`investigate the effect of UCN-01 on cell cycle arrest in human tumor cells,
`one of ordinary skill in the art would have found reason to combine their
`teachings. See id.
`Accordingly, our Decision holding claims 1–3, 5, and 6 unpatentable
`under Ground IV is supported by substantial evidence irrespective of
`whether one of ordinary skill in the art would have understood that UCN-01
`inhibits c-src in human and animal cells. We, nonetheless, address the
`specifics of Patent Owner’s arguments.
`
`A.
`
`Robinson
`In our Decision, we rejected Patent Owner’s contention that although
`Akinaga teaches that UCN-01 inhibits v-src (as does Seynaeve), one of
`ordinary skill in the art would have no reason to believe that UCN-01 would
`inhibit its cellular homolog c-src because v-src is “found only in chickens”
`and “is more difficult to inhibit.” Dec. 28, 32. We instead credited the
`testimony of Petitioner’s expert, Dr. Eastman that “[b]ecause v-Src and
`c-Src have similar structures, compounds that inhibit the tyrosine kinase
`activity of v-Src generally inhibit c-Src as well. Thus, a person of ordinary
`skill would have understood that an inhibitor of v-Src would also inhibit the
`c-Src protein present in A431 cells and other human tumors.” Id. at 33
`(quoting Ex. 1002 ¶ 202). Dr. Eastman testified that Robinson, for
`example, showed “that staurosporine, a molecule very similar to UCN-01,
`inhibited both v-Src and c-Src. . . . Thus, a person of ordinary skill in the
`art would have recognized that UCN-01 would inhibit tyrosine kinases in
`both animals and humans.” Id.
`According to Robinson, “[t]he elevation in the tyrosine-specific
`kinase activity of pp60 c-src in human carcinoma . . . is suggestive that
`appropriate tyrosine kinase inhibitors may represent a new class of cancer
`5
`
`
`
`IPR2016-01034
`Patent 7,838,512 B1
`therapeutics.” Ex. 1036, 256. Accordingly, Robinson screened a large
`number of compounds for tyrosine kinase inhibitory activity against
`isolated c-src protein, also known as pp60c-src. Id. at 255, Table 1.
`Consistent with Dr. Eastman’s testimony, Robinson reports that “[t]he most
`potent inhibitory effects [were] produced with staurosporine,” a “broad
`spectrum protein kinase inhibitor[].” Id. at 255, 257. Robinson emphasizes
`that, “[c]onsistent with previous reports, staurosporine was a potent
`inhibitor of pp60src.” Id. at 257.
`Robinson further reports that staurosporine inhibited the colony
`formation of activated c-src transformed cells in soft agar with “IC50 values
`. . . in the same range as IC50 values for the isolated c-src enzyme.” Id. at
`255. Robinson further determined that, although staurosporine and other
`agents inhibited colony formation of c-src transformed cells, they also
`inhibited the colony formation induced by different oncogenes “suggesting
`no selective inhibition of the src mediated transformation was being
`produced.” Id., Abstract. In view of these results, Robinson posits that:
`The lack of whole cell selectivity observed for staurosporine,
`quercetin, genistein and herbimycin A on oncogene transformed
`NIH3T3 cells perhaps reflects the multiple actions attributed to
`each of these agents. For example the broad spectrum of kinase
`inhibitory activity for staurosporine and the indication that
`protein kinase C may be more sensitive than pp60src to its
`inhibitory effects may be partially responsible for the equipotent
`effects produced on colony formation of the variety of NIH3T3
`transformants examined. Protein kinase C inhibition may also
`
`6
`
`
`
`IPR2016-01034
`Patent 7,838,512 B1
`be involved with the toxicity produced before any meaningful
`antitumor activity when tested in vivo.
`Id. at 257 (internal citations omitted). Robinson concludes that “the
`compounds examined do not show appropriate whole cell effects to warrant
`development efforts.” Id. at 258.
`Patent Owner now argues that because Robinson did not consider
`staurosporine a candidate for drug development as a tyrosine kinase
`inhibitor, one of ordinary skill in the art would not understand that
`staurosporine inhibits c-src in human or animal cells. See Reh’g Req. 5–6.
`Patent Owner’s argument is unsupported by expert testimony or a plain
`reading of Robinson.
`Robinson expressly identifies staurosporine as an inhibitor of c-src
`tyrosine kinase but posits that staurosporine’s effects in cellular assays may
`be due to “multiple actions.” See Ex. 1036, 257.9 In this respect, Robinson
`raises the possibility that “protein kinase C may be more sensitive” to
`staurosporine than the tyrosine kinase c-src. Id. Contrary to Patent
`Owner’s urging, we do not equate Robinson’s failure to observe an effect
`attributable to tyrosine kinase inhibition in some assays with a conclusion
`that staurosporine is not a “low molecular weight tyrosine kinase inhibitor,”
`as required by claim 1.
`We further note that Robinson evaluates the use of tyrosine kinase
`inhibitors such as staurosporine as individual antitumor agents. That
`
`
`9 Consistent with Robinson, “Tam teaches that ‘[s]taurosporine is a potent
`general protein kinase inhibitor that can suppress in vitro the activity of
`phospholipid Ca2+-dependent and cyclic nucleotide-dependent
`serine/threonine protein kinases as well as the tyrosine kinases p60v-src and
`epidermal growth factor receptor [EGFR].’” Dec. 29 (quoting Ex. 1012,
`811) (emphasis added).
`
`7
`
`
`
`IPR2016-01034
`Patent 7,838,512 B1
`Robinson determined that these compounds, administered alone, did not
`warrant further development is not dispositive in light of Akinaga’s
`teaching that a chemotherapeutic DNA damaging agent in combination with
`the tyrosine kinase inhibitor UCN-01 (as taught by Seynaeve) produces
`synergistic cytotoxic and antitumor effects.
`For the reasons set forth above, we did not overlook or misapprehend
`the evidence relating to Robinson.
`
`B.
`
`Akinaga 1991
`In our Decision, we were persuaded by Petitioner’s argument that one
`of ordinary skill in the art would have had a reason to combine Akinaga
`with Seynaeve, Tam, and Friedman “because they involve administration of
`the same tyrosine kinase inhibit (UCN-01) or its close structural analog
`[staurosporine], which has substantially similar effects on the cell cycle.”
`Dec. 37–38. In its Rehearing Request, Patent Owner argues that we
`misapprehended the evidence supporting Petitioner’s argument that “a
`person of ordinary skill would understand that a compound that inhibits v-
`src also would inhibit c-src” in light of Akinaga 1991.10 Reh’g Req. 7.
`According to Patent Owner, Akinaga 1991 demonstrated “significant
`differences in activity, selectivity, and potency” between “UCN-01 and
`staurosporine,” which is “compelling evidence that the mechanisms of
`action between UCN-01 and staurosporine are indeed different.” Id. at 8–9;
`see, e.g., Ex. 1035, Abstract (indicating that while staurosporine was 9 to 90
`times more potent at inhibiting growth of tumor lines in vitro, only UCN-01
`
`
`10 Shiro Akinaga et al., Antitumor Activity of UCN-01, a Selective Inhibitor
`of Protein Kinase C, in Murine and Human Tumor Models, 51 CANCER
`RES. 4888–92 (1991). Ex. 1035.
`
`8
`
`
`
`IPR2016-01034
`Patent 7,838,512 B1
`showed antitumor effects in xenograft models). Patent Owner further
`argues that Akinaga 1991 ascribes these functional differences between the
`two molecules as the result of “a hydroxyl at the C-7 position of the
`indolocarbazole moiety of staurosporine.” Reh’g Req. 10.
`According to Patent Owner, Akinaga 1991 “shows that UCN-01 and
`staurosporine differ in a material way in mechanism of action and in
`structure, and thus people of ordinary skill in the art would not assume that
`UCN-01 and staurosporine have the same inhibitory behavior.” Id. at 2.
`Patent Owner, again, cites no expert testimony supporting its view of the
`understanding of one of ordinary skill in the art. In contrast, Dr. Eastman
`provided evidence that both molecules had similar effects on EGFR binding
`and were known to compete with ATP binding in the same way. Ex. 1002
`¶¶ 223–225. Because neither Dr. Eastman’s testimony, nor Petitioner’s
`arguments, demand that UCN-01 and staurosporine exhibit the same
`“activity, selectivity or potency,” as Patent Owner appears to suggest (see
`Reh’g Req. at 8–9), we credit Dr. Eastman’s testimony that: “As both
`staurosporine and UCN-01 were known to have this mechanism of action, a
`person of ordinary skill in the art would have logically predicted that UCN-
`01 would also inhibit EGF-stimulated tyrosine kinase activity.” Id. ¶ 224.
`
`Finally, Patent Owner asserts that Dr. Eastman’s reasons for
`combining the asserted references are “conclusory and refuted by record
`evidence,” because Akinaga 1993 and Tam showed that UCN-01 and
`staurosporine, respectively, showed different effects on cell cycle
`progression in different model systems. See Reh’g Req. 10–11.11 In
`
`
`11 Patent Owner also contends that at the Oral Hearing, we described
`Dr. Eastman’s reasons for combining the cited references as “pretty cryptic.”
`9
`
`
`
`IPR2016-01034
`Patent 7,838,512 B1
`particular, Patent Owner notes that Akinaga showed that UCN-01,
`administered alone “arrested the cell cycle transiently at the G1 phase,”
`whereas Tam showed that staurosporine was able to override G2 arrest
`induced by DNA damage. See id. at 11. Patent Owner presents no
`persuasive evidence regarding how one of ordinary skill in the art would
`have viewed a comparison carried out under such diverse conditions. Nor
`does Patent Owner address Akinaga’s finding that in combination with a
`DNA damaging agent—conditions more akin to those of Tam—UCN-01
`resulted in a prolongation of the S (DNA synthesis) stage of the cell cycle.
`See Ex. 1004, 187 (“In contrast, the combination of both drugs caused a S
`phase prolongation of 48 h (Fig. 4D).”). Accordingly, based on the totality
`of the record, we accept Dr. Eastman’s testimony that one of ordinary skill
`in the art would have had reason to combine the cited references. See Dec.
`37.
`
`In view of the above, we did not overlook or misapprehend the
`evidence relating to Akinaga 1991.
`
`For the reasons given, it is
`
` ORDER
`
`ORDERED that Patent Owner’s Request for Rehearing is denied;
`
`FURTHER ORDERED that our Final Written Decision of September 11,
`2017, is republished solely to eliminate unintended font changes; Paper 43 is
`expunged.
`
`
`Reh’g Req 10. We disagree with Patent Owner’s interpretation as the
`transcript clearly shows that we were referring to Petitioner’s demonstrative
`slides 39 and 40. See Ex. 42, 38:10–16.
`10
`
`
`
`IPR2016-01034
`Patent 7,838,512 B1
`
`
`
`
`PETITIONER:
`WILMER CULTER PICKERING HALE and DORR LLP
`
`David L. Cavanaugh
`David.cavanaugh@wilmerhale.com
`
`Emily R. Whelan
`Emily.whelan@wilmerhale.com
`
`Heather M. Petruzzi
`Heather.petruzzi@wilmerhale.com
`
`MORRISON & FOERSTER LLP
`
`Matthew Kreeger
`mkreeger@mofo.com
`
`Matthew Chivvis
`mchivvis@mofo.com
`
`
`
`PATENT OWNER:
`
`Christopher Freking
`chris@ntknet.com
`
`
`11
`
`